Literature DB >> 28293974

Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.

Martin Lagging1, Rune Wejstål1,2, Gunnar Norkrans1, Olle Karlström3, Soo Aleman4, Ola Weiland4, Maria Castedal5, Johan Westin1.   

Abstract

In a recent expert meeting, Swedish recommendations for the treatment of hepatitis C virus (HCV) infection were updated. An interferon-free combination of direct-acting antiviral agents is considered and indicated for all patients with chronic HCV infection, but the ability to treat all is limited primarily by high cost of medication. The group of patients prioritized for therapeutic intervention has been extended to also include fertile women desiring to become pregnant. A more thorough discussion of treatment for people who inject drugs (PWIDs) in order to diminish transmission is included, and the clinical significance of baseline NS5A resistance associated variants (RAVs), also known as resistance associated substitutions (RASs), for the treatment of HCV genotype 1a or 3 infection is discussed.

Entities:  

Keywords:  Children; Chronic kidney disease; Direct-acting antiviral agents; Genotype; Guidelines; HIV co-infection; Hepatitis C virus; People who inject drugs; Resistance associated substitutions; Resistance associated variants

Mesh:

Substances:

Year:  2017        PMID: 28293974     DOI: 10.1080/23744235.2017.1300682

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  2 in total

1.  Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.

Authors:  Sarah Blach; Marianne Blomé; Ann-Sofi Duberg; Anna Jerkeman; Martin Kåberg; Per-Erik Klasa; Martin Lagging; Devin Razavi-Shearer; Homie Razavi; Soo Aleman
Journal:  Liver Int       Date:  2021-06-30       Impact factor: 8.754

2.  Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.

Authors:  Tatsuo Kanda; Shin Yasui; Masato Nakamura; Eiichiro Suzuki; Makoto Arai; Yoshihiko Ooka; Sadahisa Ogasawara; Tetsuhiro Chiba; Tomoko Saito; Yuki Haga; Koji Takahashi; Reina Sasaki; Shuang Wu; Shingo Nakamoto; Akinobu Tawada; Hitoshi Maruyama; Fumio Imazeki; Naoya Kato; Osamu Yokosuka
Journal:  Int J Mol Sci       Date:  2017-04-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.